---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-054371"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T09:13:32.476586+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split

## Summary
- Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).
- Not eligible for standard compliance period due to prior reverse stock splits; plans to request a hearing.
- Effected 1-for-20 reverse stock split on June 13, 2025; closing bid price was $7.31.
- No assurance that bid price will remain above $1.00 or that hearing will grant continued listing.
- Common stock (CERO) and warrants (CEROW) continue trading on Nasdaq pending hearing outcome.

## SEC filing metadata
- accession: 0001213900-25-054371
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/0001213900-25-054371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/ea0245650-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-054371
- JSON: https://secwatch.observer/filing/0001213900-25-054371.json
- Plain text: https://secwatch.observer/filing/0001213900-25-054371.txt

## Key facts
- Listing & Compliance Notices
  CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: June 11, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter (the “Bid Price Requirement Letter”) from the Listing Qualifications Department (the “Staff”) at The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between April 25, 2025 through June 9, 2025, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/0001213900-25-054371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.